Logic's Mint E-Cigarette Approval Revoked by FDA Center Director Despite Scientists' Advice

Dec.16.2022
Logic's Mint E-Cigarette Approval Revoked by FDA Center Director Despite Scientists' Advice
FDA allowed the director of CTP to disregard scientific advice and revoke approval for Logic's menthol e-cigarette.

Recently, according to the third circuit memorandum of the United States Court of Appeals, lawyers for Logic company alleged that the director of the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA), Brian King, allowed for the dismissal of recommendations from FDA scientists and revoked the market approval for Logic Technology's menthol electronic cigarette products.


A motion has been filed with Logic Corporation to suspend the marketing injunction (MDO) against its menthol e-cigarette products, and new documents have been provided to the company.


According to lawyers from Troutman Pepper, new documents being reviewed by Vapor Voice reveal an unusual fact: the Center for Tobacco Products' (CTP) Office of Science (OS) revoked its science-based recommendations for the marketing authorization order of Logic's mint-flavored electronic cigarette (ENDS) prior to its pre-market tobacco product application (PMTA) being approved, after pressure from the new CTP director and the Office of Compliance and Enforcement's (OCE) center director.


According to Logic's lawyer, the company claims the right to retain their mint-flavored product in the MDO of the institution because the Office of the Center Director (OCD) overturned the Office of Science's (OS) approval of Logic's "science-based assessment" and preliminary recommendation for their product. However, the memorandum states that mint is classified as a product that will be "disfavored", and Logic is seeking court recognition that the institution's actions, based on an "unpublished, comprehensive policy" and "product-specific decisions" that were not subject to notice or comment rules, were "arbitrary and capricious".


In the October 25 memo, the operating system stated that it evaluated Logic Company's pre-market tobacco product application (PMTA), including its product-specific evidence, and concluded that the authorization of marketing Logic's menthol-flavored ENDS is appropriate for protecting public health (APPH). However, the memo reveals that the operating system only changed course after the director of the new Center for Tobacco Products (CTP) and the Office of Center Director (OCD) reached the conclusion that menthol-flavored ENDS should be considered a "disfavored" product category despite conflicting evidence, as reported by the Office of Science (OS).


The OS memorandum stated, "From a policy perspective, at the time, OS believed that as long as menthol cigarettes were still on the market, menthol-flavored ENDS could directly replace them, providing a less harmful alternative for smokers of menthol cigarettes. Compared to non-menthol smokers, they were less likely to successfully quit smoking.


According to OS, this suggests that there are potential benefits in increasing usage and transition opportunities, and evidence specific to certain products suggests that even ENDS products that are no greater than tobacco-flavored could have a greater potential for smoking cessation or significant reduction in smoking.


Subsequently, OCD raised questions about OS's recommendations, including the adequacy and relevance of scientific literature regarding the differing preferences of adult menthol smokers for menthol, ultimately indicating possible behavioral changes. OCD also highlighted concerns about the significant appeal of menthol to young people. As of July 2022, the decision on Logic PMTA was still pending when CTP transitioned to Brian King as the new center director.


According to a memorandum, OS shared their views with the newly appointed center director and openly discussed various topics including literature, clinical studies related to Logic, usage risks, and potential post-marketing requirements. Following the meeting, a senior scientific consultant specializing in OCD shared their perspective with OS, highlighting the significant risks to young people and the lack of evidence supporting the practical difference between using tobacco flavoring versus menthol flavoring. As a result, the approach to menthol flavoring should be the same as other flavorings, only approving products if evidence shows that the benefits of menthol flavoring outweigh the risks to young people. This led OS to change their direction and their approval of Logic marketing.


The second memo restated the same policy shift and suggested convening a meeting to address concerns raised by operating system personnel about the appropriateness of the decision-making process behind the refusal of Logic peppermint PMTA. The operating system also expressed concern that the new OCD method would eliminate all ENDS products that do not contain tobacco flavors.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

KT&G to Cancel All 10.87 Million Treasury Shares on April 23
KT&G to Cancel All 10.87 Million Treasury Shares on April 23
KT&G disclosed on April 16 that it will cancel all 10.87 million treasury shares it currently holds, with the planned cancellation amounting to about KRW 1.85 trillion,(USD 1.26 billion). The cancellation date is scheduled for April 23.
Apr.17 by 2FIRSTS.ai
 Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
According to The Wall Street Journal, nicotine pouch brand Zyn has rapidly gained popularity across the Trump administration and conservative political circles, including among U.S. Health Secretary Robert F. Kennedy Jr.
Business
May.20
New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
According to Law360, a federal judge ruled that makers and distributors of flavored vape brands such as Puff Bar cannot escape New York’s lawsuit seeking to hold them responsible for the youth vaping epidemic. The court found that the state had adequately alleged the companies misrepresented how safe vaping is.
Apr.07 by 2FIRSTS.ai
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
AIR Limited and Cantor Equity Partners III, Inc. announced that AIR and AIR Holdings Limited have filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission in connection with their previously announced proposed business combination. Upon closing, the combined company, AIR Global PLC, is expected to be listed on Nasdaq in the United States under the ticker symbol “AIIR.”
Mar.31 by 2FIRSTS.ai
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 1.188 billion, down 21.78% year on year, while net profit attributable to shareholders rose 30.00% to RMB 58.94 million. In the first quarter of 2026, revenue was RMB 291.51 million, down 10.34% year on year, while attributable net profit rose 49.94% to RMB 19.98 million.
Apr.29 by 2FIRSTS.ai